Penumbra (NYSE:PEN) Rating Lowered to Hold at Wall Street Zen

Penumbra (NYSE:PEN) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Other research analysts have also recently issued reports about the stock. Citigroup cut shares of Penumbra from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $350.00 to $374.00 in a report on Thursday. Evercore ISI reaffirmed an “outperform” rating and issued a $340.00 target price on shares of Penumbra in a research report on Monday, January 5th. Bank of America boosted their target price on shares of Penumbra from $320.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Robert W. Baird reissued a “neutral” rating and set a $374.00 price target (up from $345.00) on shares of Penumbra in a report on Friday. Finally, Truist Financial lowered Penumbra from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $370.00 to $374.00 in a report on Friday. Seven research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $355.88.

Penumbra Trading Up 0.1%

Shares of NYSE:PEN opened at $350.93 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18. Penumbra has a 1 year low of $221.26 and a 1 year high of $352.15. The company has a market cap of $13.74 billion, a P/E ratio of 83.95, a PEG ratio of 2.14 and a beta of 0.71. The stock’s fifty day moving average price is $303.54 and its 200-day moving average price is $269.79.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.90 by $0.07. The company had revenue of $354.69 million during the quarter, compared to the consensus estimate of $340.77 million. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.Penumbra’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same period last year, the company earned $0.85 EPS. Sell-side analysts expect that Penumbra will post 3.67 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Harpreet Grewal sold 186 shares of Penumbra stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $227.58, for a total transaction of $42,329.88. Following the transaction, the director directly owned 8,516 shares in the company, valued at approximately $1,938,071.28. The trade was a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arani Bose sold 15,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $308.82, for a total value of $4,632,300.00. Following the sale, the director directly owned 258,462 shares of the company’s stock, valued at $79,818,234.84. This represents a 5.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 34,144 shares of company stock valued at $10,260,127 in the last 90 days. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Penumbra

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC boosted its stake in shares of Penumbra by 14.5% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,584 shares of the company’s stock worth $2,358,000 after acquiring an additional 959 shares during the period. Fiduciary Financial Group LLC purchased a new position in Penumbra in the 4th quarter worth approximately $218,000. Legacy Wealth Asset Management LLC lifted its holdings in Penumbra by 4.6% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 1,581 shares of the company’s stock worth $492,000 after purchasing an additional 70 shares in the last quarter. SG Americas Securities LLC boosted its stake in Penumbra by 144.4% in the 4th quarter. SG Americas Securities LLC now owns 11,111 shares of the company’s stock worth $3,455,000 after purchasing an additional 6,564 shares during the period. Finally, Diversified Trust Co. grew its holdings in Penumbra by 10.4% during the 4th quarter. Diversified Trust Co. now owns 7,448 shares of the company’s stock valued at $2,316,000 after buying an additional 703 shares in the last quarter. Institutional investors own 88.88% of the company’s stock.

Key Penumbra News

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.